- Home
- WIA vs OBIO Comparison
WIA vs OBIO Comparison
Compare WIA & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- OBIO
- Stock Information
- Founded
- WIA 2003
- OBIO 2017
- Country
- WIA United States
- OBIO United States
- Employees
- WIA N/A
- OBIO N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- WIA Finance
- OBIO Health Care
- Exchange
- WIA Nasdaq
- OBIO Nasdaq
- Market Cap
- WIA 191.5M
- OBIO 198.2M
- IPO Year
- WIA N/A
- OBIO N/A
- Fundamental
- Price
- WIA $8.21
- OBIO $4.72
- Analyst Decision
- WIA
- OBIO Strong Buy
- Analyst Count
- WIA 0
- OBIO 4
- Target Price
- WIA N/A
- OBIO $16.25
- AVG Volume (30 Days)
- WIA 39.2K
- OBIO 50.3K
- Earning Date
- WIA 01-01-0001
- OBIO 03-26-2025
- Dividend Yield
- WIA 12.29%
- OBIO N/A
- EPS Growth
- WIA N/A
- OBIO N/A
- EPS
- WIA N/A
- OBIO N/A
- Revenue
- WIA N/A
- OBIO $2,647,000.00
- Revenue This Year
- WIA N/A
- OBIO $22.61
- Revenue Next Year
- WIA N/A
- OBIO $16.64
- P/E Ratio
- WIA N/A
- OBIO N/A
- Revenue Growth
- WIA N/A
- OBIO N/A
- 52 Week Low
- WIA $7.56
- OBIO $3.96
- 52 Week High
- WIA $8.91
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- WIA 55.39
- OBIO 38.59
- Support Level
- WIA $8.02
- OBIO $5.20
- Resistance Level
- WIA $8.35
- OBIO $5.98
- Average True Range (ATR)
- WIA 0.10
- OBIO 0.42
- MACD
- WIA 0.00
- OBIO -0.07
- Stochastic Oscillator
- WIA 57.58
- OBIO 2.70
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.